The Role of Lipopolysaccharide-Binding Protein in Hepatitis B-Related Cirrhosis: Is There a Link to Portal Hypertension?
), Suyata -(2), Legiran -(3), Imam Suprianto(4), Vidi Orba Busro(5), Muhamad Ayus Astoni(6), Anjab Akmal Sya'roni(7),
(1) Fellow in Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya /Mohammad Hoesin General Hospital, Palembang / Department of Internal Medicine, Faculty of Medicine, UniversitasBengkulu/Mohammad Yunus Regional Hospital, Bengkulu
(2) Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Mohammad Hoesin General Hospital, Palembang
(3) Department of Anatomy, Faculty of Medicine, Universitas Sriwijaya
(4) Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Mohammad Hoesin General Hospital, Palembang
(5) Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Mohammad Hoesin General Hospital, Palembang
(6) Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Mohammad Hoesin General Hospital, Palembang
(7) Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Mohammad Hoesin General Hospital, Palembang
Corresponding Author
Abstract
Background: Bacterial translocation plays a critical role in the pathogenesis of systemic inflammation in cirrhosis, particularly in cases related to chronic Hepatitis B infection. Lipopolysaccharide-binding protein (LBP) is a key acute-phase reactant that reflects exposure to endotoxins, yet its relationship with portal hypertension remains poorly defined. This study aimed to evaluate the correlation between serum LBP levels and spleen stiffness, a non-invasive marker of portal hypertension in patients with Hepatitis B-related cirrhosis.
Methods: A cross-sectional study was conducted on 50 patients with Hepatitis B-related cirrhosis at Dr. Mohammad Hoesin Hospital, Palembang, between September and December 2024. Serum LBP levels were measured, and spleen stiffness was assessed using transient elastography. Laboratory parameters, clinical characteristics, and virologic profiles were analyzed. Correlation analyses were performed using Pearson’s or Spearman’s correlation tests, as appropriate.
Results: The mean serum LBP level was 20.49 ± 7.34 μg/mL, while the mean spleen stiffness was 71.69 ± 17.74 kPa. A negative but non-significant correlation was observed between serum LBP levels and spleen stiffness (r = -0.263, p = 0.065). Serum LBP levels showed significant negative correlations with total, direct, and indirect bilirubin levels, as well as transaminase levels (AST and ALT), but not with platelet count, HBV DNA levels, or coagulation parameters.
Conclusion: In patients with Hepatitis B-related cirrhosis, serum LBP may reflect systemic inflammatory activity rather than the severity of portal hypertension. Further studies are needed to determine its prognostic value in cirrhotic complications.
Keywords
References
Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):524–37.
Lusida MI, Juniastuti, Yano Y. Current hepatitis B virus infection situation in Indonesia and its genetic diversity. World J Gastroenterol. 2016 Aug 28;22(32):7264–74.
H Muljono D. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian J Hepatogastroenterol. 2017;7(1):55–9.
Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. World J Gastroenterol. 2015 Oct 14;21(38):10714–20.
Lim SG, Amarapurkar DN, Chan HLY, Crawford DH, Gane EJ, Han KH, et al. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int. 2015 Jan 1;9(1):43–51.
Jasirwan COM. Adakah Perubahan Kesintasan Karsinoma Sel Hati di Indonesia? JPDI. 2020 Oct 2;7(3):133.
Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology. 2022 Jul 1;12(4):1150–74.
Jagdish RK, Roy A, Kumar K, Premkumar M, Sharma M, Rao PN, et al. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. Front Med [Internet]. 2023 Jun 15 [cited 2025 Jun 6];10. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1060073/full
Kulkarni AV, Rabiee A, Mohanty A. Management of Portal Hypertension. Journal of Clinical and Experimental Hepatology. 2022 Jul 1;12(4):1184–99.
Garcia-Pagàn JC, Schepis F, Gaba RC, Zanetto A, Perez-Campuzano V, Haskal ZJ, et al. HVPG as a Gold Standard: Accuracy Is Essential. In: de Franchis R, editor. Portal Hypertension VII. Cham: Springer International Publishing; 2022. p. 45–60.
Franchis R de, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII – Renewing consensus in portal hypertension. Journal of Hepatology. 2022 Apr 1;76(4):959–74.
Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024 May;79(5):1180.
Kurniawan J, Sulaiman AS, Lesmana CRA, Bayupurnama P, Bestari MB, Akil F, et al. National Consensus on Portal Hypertension Management in Indonesia. Acta Med Indones. 2022 Apr;54(2):324–46.
Juanola O, Francés R, Caparrós E. Exploring the Relationship between Liver Disease, Bacterial Translocation, and Dysbiosis: Unveiling the Gut-Liver Axis. Visceral Medicine. 2024 Jan 23;40(1):12–9.
Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med. 1999 Mar;37(3):271–4.
Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol. 2017;30(5):486–97.
Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, Daikos GL, et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver International. 2017;37(4):576–82.
Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37(1):208–17.
Gioia S, Carnevale R, Tavano D, Overi D, Ridola L, Nardelli S, et al. Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension. Alimentary Pharmacology & Therapeutics. 2023;58(11–12):1205–16.
Chuang CL, Huang HC, Chang CC, Lee FY, Wu JC, Lee JY, et al. Lipopolysaccharide enhanced renal vascular response to endothelin-1 through ETA overexpression in portal hypertensive rats. Journal of Gastroenterology and Hepatology. 2015;30(1):199–207.
Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction. Int Immunol. 2022 Sep 6;34(9):455–66.
Kumar R, Kumar S, Prakash SS. Compensated liver cirrhosis: Natural course and disease-modifying strategies. World J Methodol. 2023 Sep 20;13(4):179–93.
Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. Journal of Hepatology. 2021 Jul 1;75:S49–66.
Du L, Deng H, Wu X, Liu F, Yin T, Zheng J. Relationship Between Spleen Pathologic Changes and Spleen Stiffness in Portal Hypertension Rat Model. Ultrasound in Medicine & Biology. 2024 Feb 1;50(2):216–23.
Simbrunner B, Caparrós E, Neuwirth T, Schwabl P, Königshofer P, Bauer D, et al. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response. Hepatol Int. 2023 Aug;17(4):1045–56.
Rigamonti C. Spleen stiffness in portal hypertension algorithms: the next advance. The Lancet Gastroenterology & Hepatology. 2024 Dec 1;9(12):1067–9.
Schnabl B, Brenner DA. Interactions Between the Intestinal Microbiome and Liver Diseases. Gastroenterology. 2014 May 1;146(6):1513–24.
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017 Dec 14;9(6):7204–18.
Tuomi K, Logomarsino JV. Bacterial Lipopolysaccharide, Lipopolysaccharide-Binding Protein, and Other Inflammatory Markers in Obesity and After Bariatric Surgery. Metabolic Syndrome and Related Disorders. 2016 Aug;14(6):279–88.
Milbank E, Díaz-Trelles R, Dragano N, Latorre J, Mukthavaram R, Mayneris-Perxachs J, et al. Liver lipopolysaccharide binding protein prevents hepatic inflammation in physiological and pathological non-obesogenic conditions. Pharmacological Research. 2023 Jan 1;187:106562.
Article Metrics
Abstract View
: 136 times
Download : 42 times
DOI: 10.24871/2722026111-118
Refbacks
- There are currently no refbacks.
